Evaxion A (EVAX) Income from Continuing Operations (2020 - 2026)
Evaxion A (EVAX) reported Income from Continuing Operations of 3398000.0 for Q1 2026, down 73.01% on a YoY basis from 12591833.96 in Q1 2025, and down 170.85% quarter-over-quarter from 4796000.0 in Q4 2025.
Evaxion A (EVAX) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Evaxion A has reported Income from Continuing Operations for 7 years, with the latest figure at 3398000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 73.01% year-over-year to 3398000.0; the trailing twelve-month figure through Mar 2026 stood at 6023000.0 (up 140.52% YoY), and the FY2025 full-year result was 9523000.0, up 21.58% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 3398000.0, down from 4796000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 9846000.0 in Q3 2025, with the low at 7218000.0 in Q4 2022.
- Historically, Income from Continuing Operations has averaged 3323823.53 across 5 years, with a median of 5122000.0 in 2022.
- The largest YoY upside for Income from Continuing Operations was 562.91% in 2025 against a maximum downside of 359.1% in 2025.
- Evaxion A's Income from Continuing Operations stood at 7218000.0 in 2022, then soared by 32.43% to 4877000.0 in 2023, then climbed by 14.31% to 4179000.0 in 2024, then jumped by 214.76% to 4796000.0 in 2025, then plunged by 170.85% to 3398000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 3398000.0 (Q1 2026), 4796000.0 (Q4 2025), and 9846000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 727.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.40 Mn |
| Dec 31, 2025 | 4.80 Mn |
| Sep 30, 2025 | 9.85 Mn |
| Jun 30, 2025 | -5.22 Mn |
| Mar 31, 2025 | -1.96 Mn |
| Dec 31, 2024 | -4.18 Mn |
| Sep 30, 2024 | -2.13 Mn |
| Jun 30, 2024 | -6.60 Mn |
| Mar 31, 2024 | 758,000.00 |
| Dec 31, 2023 | -4.88 Mn |
| Sep 30, 2023 | -6.07 Mn |
| Jun 30, 2023 | -6.13 Mn |
| Mar 31, 2023 | -6.63 Mn |
| Dec 31, 2022 | -7.22 Mn |
| Sep 30, 2022 | -6.09 Mn |
| Jun 30, 2022 | -5.12 Mn |
| Mar 31, 2022 | -6.29 Mn |
| Dec 31, 2021 | -5.72 Mn |
| Sep 30, 2021 | -6.10 Mn |
| Jun 30, 2021 | -8.16 Mn |